The combination of expression of these three receptors can be used to group breast cancer tumours into four main molecular subtypes: luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.